Stem cell-derived islet cells for transplantation

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose of Review: The promise of islet transplantation for type 1 diabetes has been hampered by the lack of a renewable source of insulin-producing cells. However, steadfast advances in the field have set the stage for stem cell-based approaches to take over in the near future. This review focuses on the most intriguing findings reported in recent years, which include not only progress in adult and embryonic stem cell differentiation, but also the direct reprogramming of nonendocrine tissues into insulin-producing beta cells. Recent Findings: In spite of their potential for tumorigenesis, human embryonic stem (hES) cells are poised to be in clinical trials within the next decade. This situation is mainly due to the preclinical success of a differentiation method that recapitulates beta cell development. In contrast, adult stem cells still need one such gold standard of differentiation, and progress is somewhat impeded by the lack of consensus on the best source. A concerted effort is necessary to bring their potential to clinical fruition. In the meantime, reported success in reprogramming might offer a 'third way' towards the rescue of pancreatic endocrine function. Summary: Here we discuss the important strategic decisions that need to be made in order to maximize the therapeutic chances of each of the presented approaches.

Original languageEnglish
Pages (from-to)76-82
Number of pages7
JournalCurrent Opinion in Organ Transplantation
Volume16
Issue number1
DOIs
StatePublished - Feb 1 2011

Fingerprint

Islets of Langerhans Transplantation
Cell Transplantation
Islets of Langerhans
Adult Stem Cells
Stem Cells
Insulin
Embryonic Stem Cells
Type 1 Diabetes Mellitus
Cell Differentiation
Carcinogenesis
Clinical Trials
Therapeutics

Keywords

  • beta cell differentiation
  • human embryonic stem cells
  • induced pluripotent stem cells
  • islet transplantation
  • mesenchymal stem cells
  • reprogramming

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

Stem cell-derived islet cells for transplantation. / Dominguez-Bendala, Juan; Inverardi, Luca A; Ricordi, Camillo.

In: Current Opinion in Organ Transplantation, Vol. 16, No. 1, 01.02.2011, p. 76-82.

Research output: Contribution to journalArticle

@article{86f9f5aecff0472582c1bccb3c72b2c2,
title = "Stem cell-derived islet cells for transplantation",
abstract = "Purpose of Review: The promise of islet transplantation for type 1 diabetes has been hampered by the lack of a renewable source of insulin-producing cells. However, steadfast advances in the field have set the stage for stem cell-based approaches to take over in the near future. This review focuses on the most intriguing findings reported in recent years, which include not only progress in adult and embryonic stem cell differentiation, but also the direct reprogramming of nonendocrine tissues into insulin-producing beta cells. Recent Findings: In spite of their potential for tumorigenesis, human embryonic stem (hES) cells are poised to be in clinical trials within the next decade. This situation is mainly due to the preclinical success of a differentiation method that recapitulates beta cell development. In contrast, adult stem cells still need one such gold standard of differentiation, and progress is somewhat impeded by the lack of consensus on the best source. A concerted effort is necessary to bring their potential to clinical fruition. In the meantime, reported success in reprogramming might offer a 'third way' towards the rescue of pancreatic endocrine function. Summary: Here we discuss the important strategic decisions that need to be made in order to maximize the therapeutic chances of each of the presented approaches.",
keywords = "beta cell differentiation, human embryonic stem cells, induced pluripotent stem cells, islet transplantation, mesenchymal stem cells, reprogramming",
author = "Juan Dominguez-Bendala and Inverardi, {Luca A} and Camillo Ricordi",
year = "2011",
month = "2",
day = "1",
doi = "10.1097/MOT.0b013e32834252b5",
language = "English",
volume = "16",
pages = "76--82",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Stem cell-derived islet cells for transplantation

AU - Dominguez-Bendala, Juan

AU - Inverardi, Luca A

AU - Ricordi, Camillo

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Purpose of Review: The promise of islet transplantation for type 1 diabetes has been hampered by the lack of a renewable source of insulin-producing cells. However, steadfast advances in the field have set the stage for stem cell-based approaches to take over in the near future. This review focuses on the most intriguing findings reported in recent years, which include not only progress in adult and embryonic stem cell differentiation, but also the direct reprogramming of nonendocrine tissues into insulin-producing beta cells. Recent Findings: In spite of their potential for tumorigenesis, human embryonic stem (hES) cells are poised to be in clinical trials within the next decade. This situation is mainly due to the preclinical success of a differentiation method that recapitulates beta cell development. In contrast, adult stem cells still need one such gold standard of differentiation, and progress is somewhat impeded by the lack of consensus on the best source. A concerted effort is necessary to bring their potential to clinical fruition. In the meantime, reported success in reprogramming might offer a 'third way' towards the rescue of pancreatic endocrine function. Summary: Here we discuss the important strategic decisions that need to be made in order to maximize the therapeutic chances of each of the presented approaches.

AB - Purpose of Review: The promise of islet transplantation for type 1 diabetes has been hampered by the lack of a renewable source of insulin-producing cells. However, steadfast advances in the field have set the stage for stem cell-based approaches to take over in the near future. This review focuses on the most intriguing findings reported in recent years, which include not only progress in adult and embryonic stem cell differentiation, but also the direct reprogramming of nonendocrine tissues into insulin-producing beta cells. Recent Findings: In spite of their potential for tumorigenesis, human embryonic stem (hES) cells are poised to be in clinical trials within the next decade. This situation is mainly due to the preclinical success of a differentiation method that recapitulates beta cell development. In contrast, adult stem cells still need one such gold standard of differentiation, and progress is somewhat impeded by the lack of consensus on the best source. A concerted effort is necessary to bring their potential to clinical fruition. In the meantime, reported success in reprogramming might offer a 'third way' towards the rescue of pancreatic endocrine function. Summary: Here we discuss the important strategic decisions that need to be made in order to maximize the therapeutic chances of each of the presented approaches.

KW - beta cell differentiation

KW - human embryonic stem cells

KW - induced pluripotent stem cells

KW - islet transplantation

KW - mesenchymal stem cells

KW - reprogramming

UR - http://www.scopus.com/inward/record.url?scp=78751628296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751628296&partnerID=8YFLogxK

U2 - 10.1097/MOT.0b013e32834252b5

DO - 10.1097/MOT.0b013e32834252b5

M3 - Article

C2 - 21150613

AN - SCOPUS:78751628296

VL - 16

SP - 76

EP - 82

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 1

ER -